- WPD Pharmaceuticals Inc. (WBIO) (FSE: 8SV1) secures indefinite sublicense rights for its cancer fighting agent Berubicin
- The company has successfully used ‘commercially reasonable development efforts’ towards the advancement of Berubicin
- Berubicin is an anthracycline, a class of anticancer agents
- At least US$2 million was spent towards advancing the agent
- WPD Pharmaceuticals Inc. (WBIO) is unchanged trading at $0.08 per share as of 10:53 a.m. EST
WPD Pharmaceuticals Inc. (WBIO) has secured indefinite sublicense rights for its cancer-fighting agent Berubicin.
CNS stated WPD Pharmaceuticals has successfully used ‘commercially reasonable development efforts towards the advancement of Berubicin.
Berubicin is effective against more types of cancer than any other class of chemotherapeutic agents.
At least US$2 million was spent on the development, testing, regulatory approval, and commercialization of the licensed product during the applicable period.
As such, WPD Pharmaceuticals (through WPD Poland) is entitled to maintain its sublicense of Berubicin.
The company’s sub-license of Berubicin provides geographic exclusivity for development and marketing in select Eastern Europe and Central Asian countries.
Anthracyclines are designed to utilize natural processes to induce DNA damage in targeted cancer cells by interfering with a critical enzyme, thus enabling cell proliferation.
Berubicin treatment of brain cancer patients appeared to demonstrate positive responses.
Treatment included one durable complete response in Phase 1 human clinical trials conducted by Reata Pharmaceuticals, Inc.
WPD Pharmaceuticals Inc. (WBIO) is unchanged trading at $0.08 per share as of 10:53 a.m. EST.
